TransCode Therapeutics reports FY2023 operating loss of $19.4M; cash $2.8M at year-end

Transcode Therapeutics, Inc.

2023-Q3 EPS reported -$0.65

Cash $2.8M as of Dec 31, 2023; net $6.2M raised in Jan 2024; funding expected into late Q3/Q4 2024.
R&D expenses $12.3M (up from $10.2M in 2022); G&A $7.2M (down from $8.4M); operating loss $19.4M.
CEO Michael Dudley resigned; CFO Tom Fitzgerald named interim CEO; Philippe Calais appointed Executive Chairman.
Phase 0 trial of TTX-MC138 completed; preliminary results suggest delivery to metastatic lesions in breast cancer patient.
Phase 1 trial of TTX-MC138 planned mid-2024 subject to FDA authorization and IRB approvals.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Transcode Therapeutics, Inc. reported financial results for the fiscal year ended December 31, 2023.

Period: the fiscal year ended December 31, 2023
Result: reported results

Exact text from the filing

On April 3, 2024, TransCode Therapeutics, Inc. issued a press release announcing its financial results and other business highlights for the fourth quarter and full year ended December 31, 2023.

View on SEC.gov

321 earnings releases filed in the last 30 days. Browse all earnings releases →

Transcode Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-044325

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.